Evidence map›Paper›PMID 35585782›Full record

Observational studyJournal of medical virology2022

SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.

Ignacio Torres, Estela Giménez, Eliseo Albert, Joao Zulaica, Beatriz Álvarez-Rodríguez, Javier S Burgos, Salvador Peiró, Ramón Limón, Hermelinda Vanaclocha, Celia Rodado and 15 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 1 country.

Ignacio TorresMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Estela GiménezMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Eliseo AlbertMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Joao ZulaicaInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Beatriz Álvarez-RodríguezInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Javier S BurgosDepartment of Health, General Directorate of Research and Healthcare Supervision, Valencia Government, Valencia, Spain.
Salvador PeiróFoundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
Ramón LimónDepartment of Health, General Directorate of Healthcare, Valencian Government, Valencia, Spain.
Hermelinda VanaclochaDepartment of Health, General Directorate of Public Health, Valencia Government, Valencia, Spain.
Celia RodadoComisión Departamental de control de Residencias, Departamento de Salud València Clínico Malvarrosa, Valencia, Spain.
Pilar BotijaDirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Amelia SifreCentro de Salud Pública, Gandía, Spain.
Borja TurCentro de Salud Pública, Gandía, Spain.
Rosa Andrés LozanoCentro de Salud Pública, Gandía, Spain.
Iria OrosaCentro de Salud Pública, Gandía, Spain.
MªÁngeles Vicente-RuizColectividades Departamento de Salud Arnau-LLiria, Valencia, Spain.
Ramón J CarriónDirección De Atención Primaria, Departamento De Salud Arnau-Lliria, Valencia, Spain.
Maria Á ClariMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
José Sánchez-PayáPreventive Medicine Service, Alicante General and University Hospital, Alicante, Spain.
Javier Díez-DomingoFoundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
Iñaki ComasBiomedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain.
Fernando González-CandelasInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
Ron GellerInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.ORCID 0000-0003-3010-4110
Valencian vaccine research program (ProVaVac) study group
Universitat de València · ESCentro de Salud Casa del Barco · ESINCLIVA Health Research Institute · ESDepartamento de Salud · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESGeneralitat Valenciana · ESGovernment of Spain · ESHospital Clínico Universitario de Valencia · ESHospital General Universitario de Alicante Doctor Balmis · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated whether peripheral blood levels of SARS-CoV-2 Spike (S) receptor binding domain antibodies (anti-RBD), neutralizing antibodies (NtAb) targeting Omicron S, and S-reactive-interferon (IFN)-γ-producing CD4

Indexed as

COVID-19COVID-19 VaccinesAged, 80 and overAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesFemaleHumansNursing HomesSARS-CoV-2Viral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesViral Envelope Proteinsanti-spike antibodiesbreakthrough infectionComirnaty® COVID-19 vaccineneutralizing antibodiesnursing home residentsSARS-CoV-2 Omicron variantspike-reactive T cells

Identifiers

PMID35585782
PMCPMC9348298
OpenAlexW4280621084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.